Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention
复制标题
DOI：
10.1111/cts.12729
复制
发表时间：
2020-01-16
影响因子：
3.9
通讯作者：
Winterstein, Almut G.
中科院分区：
文献类型：
--
作者：
El Rouby, Nihal;Alrwisan, Adel;Winterstein, Almut G.
我们的目的是评估基于小组的药物遗传学检测在经皮冠状动脉介入治疗（PCI）患者中的应用。临床药理学实施联盟（CPIC） A/B级药物在PCI术后的使用情况在IBM MarketScan受益者的全国样本中进行了估计。来自佛罗里达大学（UF）接受PCI的患者（n = 211）的基因型数据被用于在至少1年（n = 105,547）和5年（n = 12,462）随访数据的MarketScan受益人中预测基因型引导的机会。确定UF患者中基因型指导的处方机会的实际发生率。在MarketScan中，50.0%（52,799/105,547）和68.0%（8,473/12,462）的患者在1年和5年期间除了抗血小板治疗外，还开具了>= 1 CPIC A/B药物，预计1年和5年的基因型指导处方机会发生率分别为39%和52%。32%的UF患者有基因型指导的处方机会。两个队列中基因型引导机会的预测和实际发生率支持在PCI患者中使用基于小组的检测。
We aimed to estimate the utility of panel-based pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI). Utilization of Clinical Pharmacogenetic Implementation Consortium (CPIC) level A/B drugs after PCI was estimated in a national sample of IBM MarketScan beneficiaries. Genotype data from University of Florida (UF) patients (n = 211) who underwent PCI were used to project genotype-guided opportunities among MarketScan beneficiaries with at least one (N = 105,547) and five (N = 12,462) years of follow-up data. The actual incidence of genotype-guided prescribing opportunities was determined among UF patients. In MarketScan, 50.0% (52,799/105,547) over 1 year and 68.0% (8,473/12,462) over 5 years had >= 1 CPIC A/B drug besides antiplatelet therapy prescribed, with a projected incidence of genotype-guided prescribing opportunities of 39% at 1 year and 52% at 5 years. Genotype-guided prescribing opportunities occurred in 32% of UF patients. Projected and actual incidence of genotype-guided opportunities among two cohorts supports the utility of panel-based testing among patients who underwent PCI.